Atlas Capital Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Atlas Capital Advisors’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-138	Closed	-$2.25K	–	1068
2026 Q1	$2.25K	Hold	138	–	–	﹤0.01%	879
2025 Q4	$2.31K	Buy	+138	New	+$2.32K	﹤0.01%	842
2025 Q2	$1.77K	Hold	138	–	–	﹤0.01%	867
2025 Q1	$1.75K	Hold	138	–	–	﹤0.01%	909
2024 Q4	$1.81K	Buy	+138	New	+$1.99K	﹤0.01%	873
2024 Q3	–	Sell	-138	Closed	-$1.96K	–	934
2024 Q2	$1.96K	Buy	+138	New	+$1.87K	﹤0.01%	828
2024 Q1	–	Sell	-138	Closed	-$1.86K	–	927
2023 Q4	$1.86K	Hold	138	–	–	﹤0.01%	833
2023 Q3	$1.72K	Hold	138	–	–	﹤0.01%	814
2023 Q2	$1.87K	Hold	138	–	–	﹤0.01%	826
2023 Q1	$1.92K	Hold	138	–	–	﹤0.01%	836
2022 Q4	$1.96K	Hold	138	–	–	﹤0.01%	832
2022 Q3	$1.89K	Hold	138	–	–	﹤0.01%	837
2022 Q2	$1.96K	Buy	+138	New	+$2.08K	﹤0.01%	909

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Atlas Capital Advisors's HQL Position: Q2 2026 in Review

Atlas Capital Advisors sold out of abrdn Life Sciences Investors (HQL) in Q2 2026, closing a stake of 138 shares — an estimated $2.25K sold.

Atlas Capital Advisors first reported a position in HQL in Q2 2022 and held it in 13 quarters. The position peaked at $2.31K in Q4 2025. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

Atlas Capital Advisors reported no remaining abrdn Life Sciences Investors position as of Q2 2026 after selling out during the quarter.
Atlas Capital Advisors sold 138 abrdn Life Sciences Investors shares in Q2 2026, an estimated $2.25K.
Atlas Capital Advisors first reported a position in abrdn Life Sciences Investors in Q2 2022 and held it in 13 quarters.
Atlas Capital Advisors's abrdn Life Sciences Investors position peaked at $2.31K in Q4 2025.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.